Ratios Reveal: Breaking Down West Pharmaceutical Services, Inc. (WST)’s Financial Health

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

West Pharmaceutical Services, Inc. (NYSE: WST) closed the day trading at $354.41 down -1.67% from the previous closing price of $360.43. In other words, the price has decreased by -$1.67 from its previous closing price. On the day, 0.52 million shares were traded. WST stock price reached its highest trading level at $362.16 during the session, while it also had its lowest trading level at $353.63.

Ratios:

For a better understanding of WST, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 43.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 67.20. For the most recent quarter (mrq), Quick Ratio is recorded 1.95 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.06.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 07, 2024, Upgraded its rating to Buy and sets its target price to $536 from $323 previously.

On June 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $390 to $405.

Stephens Upgraded its Equal-Weight to Overweight on April 11, 2023, whereas the target price for the stock was revised from $330 to $400.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Winters Chad sold 815 shares for $358.82 per share. The transaction valued at 292,436 led to the insider holds 1,309 shares of the business.

Witherspoon Charles sold 2,019 shares of WST for $724,061 on Feb 28 ’24. The VP & Treasurer now owns 1,979 shares after completing the transaction at $358.62 per share. On Feb 27 ’24, another insider, Green Eric Mark, who serves as the President, CEO and Board Chair of the company, sold 64,132 shares for $359.85 each. As a result, the insider received 23,077,971 and left with 152,908 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WST now has a Market Capitalization of 26385399808 and an Enterprise Value of 25521143808. As of this moment, West’s Price-to-Earnings (P/E) ratio for their current fiscal year is 46.77, and their Forward P/E ratio for the next fiscal year is 39.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.86 while its Price-to-Book (P/B) ratio in mrq is 9.65. Its current Enterprise Value per Revenue stands at 8.714 whereas that against EBITDA is 31.523.

Stock Price History:

The Beta on a monthly basis for WST is 1.04, which has changed by -0.04115039 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, WST has reached a high of $415.73, while it has fallen to a 52-week low of $310.42. The 50-Day Moving Average of the stock is -5.93%, while the 200-Day Moving Average is calculated to be -4.53%.

Shares Statistics:

Over the past 3-months, WST traded about 545.36K shares per day on average, while over the past 10 days, WST traded about 515620 shares per day. A total of 73.50M shares are outstanding, with a floating share count of 72.80M. Insiders hold about 0.55% of the company’s shares, while institutions hold 95.89% stake in the company. Shares short for WST as of 1713139200 were 975857 with a Short Ratio of 1.79, compared to 1710460800 on 1209637. Therefore, it implies a Short% of Shares Outstanding of 975857 and a Short% of Float of 1.7399999999999998.

Dividends & Splits

WST’s forward annual dividend rate is 0.79, up from 0.78 a year ago. Against a Trailing Annual Dividend Yield of 0.0021640817The stock’s 5-year Average Dividend Yield is 0.26. The current Payout Ratio is 9.90% for WST, which recently paid a dividend on 2024-04-23 with an ex-dividend date of 1722384000. Stock splits for the company last occurred on 2013-09-27 when the company split stock in a 2:1 ratio.

Earnings Estimates

The performance of West Pharmaceutical Services, Inc. (WST) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.On average, analysts expect EPS of $1.78 for the current quarter, with a high estimate of $2.03 and a low estimate of $1.54, while EPS last year was $2.11. The consensus estimate for the next quarter is $2.14, with high estimates of $2.21 and low estimates of $2.06.

Analysts are recommending an EPS of between $7.89 and $7.63 for the fiscal current year, implying an average EPS of $7.71. EPS for the following year is $9.04, with 9.0 analysts recommending between $9.5 and $8.31.

Revenue Estimates

8 analysts predict $731.18M in revenue for the current quarter. It ranges from a high estimate of $765.4M to a low estimate of $705.26M. As of the current estimate, West Pharmaceutical Services, Inc.’s year-ago sales were $755.71MFor the next quarter, 8 analysts are estimating revenue of $784.78M. There is a high estimate of $790M for the next quarter, whereas the lowest estimate is $775M.

A total of 9 analysts have provided revenue estimates for WST’s current fiscal year. The highest revenue estimate was $3.02B, while the lowest revenue estimate was $3B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.95BBased on 9 analysts’ estimates, the company’s revenue will be $3.28B in the next fiscal year. The high estimate is $3.33B and the low estimate is $3.24B.

Most Popular

[the_ad id="945"]